Applied Therapeutics Inc

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company which engages in the development of a pipeline of novel products. It is targeting treatments for central nervous system rare diseases and diabetic complications. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will participate in a fireside chat at the UBS Global Healthcare Conference on Wednesday, March 25, 2022 at 10:45 a.m. ET in New York.

Applied Therapeutics to Present at the UBS Global Healthcare Conference

Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022 Continued progress in three Phase 3 trials in areas of high unmet medical need, with multiple clinical milestones expected in 2022

Applied Therapeutics Reports First Quarter 2022 Financial Results

Angion Biomedica

Bolt Biotherapeutics

Ikena Oncology

Landos Biopharma

Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.

5 Biotech Stocks Set to Outpace Q1 Earnings Estimates

NEW YORK, April 04, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced poster presentations at the 2022 43rd Annual Meeting of the Society for Inherited Metabolic Disorders, April 10 - 13, 2022 in Orlando, Florida.

Applied Therapeutics to Present at the 43rd Annual Meeting of the Society for Inherited Metabolic Disorders

NEW YORK, March 16, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced their abstract #OP005 was accepted as an oral platform presentation at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics, March 22 – 26, 2022 in Nashville, Tennessee.

Applied Therapeutics to Present at the 2022 Annual Clinical Genetics Meeting of the American College of Molecular Genetics and Genomics

Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022 Progress in Three Phase 3 Trials in Areas of High Unmet Clinical Need, with Multiple Clinical and Regulatory Milestones Expected in 2022

Applied Therapeutics Reports Fourth Quarter and Year-end 2021 Financial Results

NEW YORK, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today is recognizing the 15th Annual Rare Disease Day to help elevate awareness of rare diseases and call attention to the unique challenges facing people with rare diseases.

Applied Therapeutics Supports 15th Annual Rare Disease Day

NEW YORK, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced that it will present at the 11th Annual SVB Leerink Global Healthcare Conference on Friday, February 18, 2022 at 11:20 a.m. ET.

Applied Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Applied Therapeutics shares were hammered this month after FDA did not agree to accelerated approval for its drug candidate AT-007 in treating galactosemia in children.

Applied Therapeutics: Buying This Beaten-Down, Undervalued Rare Disease Company's Stock

NEW YORK--(BUSINESS WIRE)-- #Applied--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) on behalf of Applied Therapeutics stockholders. Our investigation concerns whether Applied Therapeutics has violated the federal securities laws and/or engaged in other unlawful business practices. Click here to participate in the action. On January 3, 2022, A

APPLIED THERAPEUTICS ALERT: Bragar Eagel & Squire, P.C. is Investigating Applied Therapeutics, Inc. on Behalf of Applied Therapeutics Stockholders and Encourages Investors to Contact the Firm

SAN FRANCISCO, Jan. 14, 2022 /PRNewswire/ -- Hagens Berman urges Applied Therapeutics, Inc. (NASDAQ: APLT) investors with significant losses to submit your losses now. The firm is investigating possible securities law violations and certain investors may have valuable claims.

APLT INVESTIGATION: Hagens Berman, National Trial Attorneys, Encourages Applied Therapeutics, Inc. (APLT) Investors to Contact Firm's Attorneys, Firm Investigating Possible Securities Law Violations

SAN DIEGO--(BUSINESS WIRE)---- $APLT #classactioninvestigation--Applied Therapeutics, Inc. (APLT) Holds Submission of New Drug Application for AT-007

SHAREHOLDER ALERT: Robbins LLP Investigates Applied Therapeutics, Inc. (APLT) on Behalf of Shareholders

NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT). Investors who purchased Applied Therapeutics shares are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/aplt. The investigation concerns whether Applied Therapeutics and certain of its officers an

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Applied Therapeutics, Inc. (APLT) Investigation

Boston, Massachusetts--(Newsfile Corp. - January 4, 2022) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Applied Therapeutics, Inc. ("AT" or the "Company") (NASDAQ: APLT), a clinical-stage biopharmaceutical company with headquarters in New York, New York.On January 3, 2022, before the market opened, the Company issued a press release providing a regulatory update on the Company's AT-007 Galactosemia program. The Company stated, among other things, that "[f]ollowing...

Berman Tabacco Announces Investigation of Applied Therapeutics, Inc. (APLT) for Potential Securities Law Violations

The company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected.

Why Applied Therapeutics Stock Is Sliding Today

Applied Therapeutics (NASDAQ: APLT) is trading significantly lower Monday after the company said it would not immediately submit a new drug application for its AT-007 for treatment of galactosemia. The Galactosemia program had previously been discussed in the context of an NDA for accelerated approval based on reduction in galactitol, but the FDA has now indicated that clinical outcomes data will likely be required for approval.

Why Applied Therapeutics Shares Are Falling Today

Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency.  Although the Galactosemia program had previously been discussed for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval.

Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the AT-007 Galactosemia program.

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced the initiation of a registrational phase 2/3 study of AT-007 in Sorbitol Dehydrogenase (SORD) Deficiency. The study, termed INSPIRE (INhibition of Sorbitol Production through Inhibition of the Aldose Reductase Enzyme), will investigate biomarker efficacy, clinical outcomes and safety in people living with SORD Deficiency treated with AT-007 vs. placebo.

Applied Therapeutics Announces Initiation of Registrational Phase 2/3 Study of AT-007 in SORD Deficiency

NEW YORK, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, has announced a symposium and poster presentations at the 14th International Congress of Inborn Errors of Metabolism (ICIEM), November 21-23, 2021, Sydney, Australia.

Applied Therapeutics to Present at the 14th International Congress of Inborn Errors of Metabolism

Data from pilot trial of AT-007 in SORD deficiency expresses substantial and significant reduction in sorbitol

Applied Therapeutics Reports Third Quarter 2021 Financial Results

Substantial and statistically significant reduction in plasma galactitol of 40% with new weight-based dosing parameters

Applied Therapeutics Reports Additional Pediatric Biomarker Data from ACTION-Galactosemia Kids

Applied Therapeutics Inc. (APLT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Applied Therapeutics Inc. (APLT) Upgraded to Buy: Here's Why

Applied Therapeutics Inc (NASDAQ: APLT) has reported initial biomarker data from the pediatric ACTION-Galactosemia Kids study and baseline analysis of the 47 children enrolled in the study. Related Content:   FDA Fast Track Review For AT-007 In Rare Metabolic Disorder.

Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead Candidate

NDA submission for AT-007 in Galactosemia expected in Q3 2021; commercial preparations ongoing

News for Applied Therapeutics Inc Stock (APLT)